Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(45,514) | $(39,876) |
| Adjustments to reconcile net loss to net cash from operating activities: | ||
| Depreciation | 463 | 622 |
| Noncash operating lease expense | 972 | 1,012 |
| Stock-based compensation | 10,797 | 7,255 |
| Accretion on marketable securities | (1,124) | (638) |
| Other, net | 21 | (56) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's D&A?
- Tango Therapeutics (TNGX) reported D&A of $463K in Q1 2026.
- How has Tango Therapeutics's D&A changed year-over-year?
- Tango Therapeutics's D&A decreased by 25.6% year-over-year, from $622K to $463K.
- What is the long-term trend for Tango Therapeutics's D&A?
- Over 4 years (2021 to 2025), Tango Therapeutics's D&A has grown at a 27.2% compound annual growth rate (CAGR), from $872K to $2.28M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Tango Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude